AAPL332.56+5.99 (+1.83%) ▲|ABBV257.01+2.01 (+0.79%) ▲|ABT102.12-1.24 (-1.20%) ▼|ACN183.71+5.80 (+3.26%) ▲|ADBE253.64+4.81 (+1.93%) ▲|AMAT457.52+3.51 (+0.77%) ▲|AMD516.23+12.63 (+2.51%) ▲|AMGN378.14-4.33 (-1.13%) ▼|AMT178.05+5.07 (+2.93%) ▲|AMZN257.23+5.34 (+2.12%) ▲|AVGO362.85+2.02 (+0.56%) ▲|AXP324.25+3.54 (+1.10%) ▲|BA210.62+5.82 (+2.84%) ▲|BAC62.73+0.17 (+0.26%) ▲|BKNG174.01+0.10 (+0.06%) ▲|BLK1,081.85+19.45 (+1.83%) ▲|BMY63.47-0.28 (-0.44%) ▼|BNY162.85+0.26 (+0.16%) ▲|BRK-B509.53+2.53 (+0.50%) ▲|C138.96+0.46 (+0.33%) ▲|CAT819.79+14.79 (+1.84%) ▲|CL86.45-1.45 (-1.65%) ▼|CMCSA25.16-0.01 (-0.04%) ▼|COF208.31+1.20 (+0.58%) ▲|COP136.75-0.30 (-0.22%) ▼|COST905.17+2.79 (+0.31%) ▲|CRM248.34+5.34 (+2.20%) ▲|CSCO111.64+4.20 (+3.91%) ▲|CVS94.47-0.82 (-0.86%) ▼|CVX213.94+1.18 (+0.55%) ▲|DE676.98-0.96 (-0.14%) ▼|DHR200.43-0.11 (-0.05%) ▼|DIS106.50+0.68 (+0.64%) ▲|DUK119.41+0.04 (+0.03%) ▲|EMR152.04+3.67 (+2.47%) ▲|FDX312.41+0.61 (+0.20%) ▲|GD356.43+2.18 (+0.62%) ▲|GE324.16+0.01 (+0.00%) ▲|GEV956.03+32.12 (+3.48%) ▲|GILD143.94-0.87 (-0.60%) ▼|GM85.70-0.42 (-0.49%) ▼|GOOG336.04+5.65 (+1.71%) ▲|GOOGL339.05+6.45 (+1.94%) ▲|GS1,028.66+8.89 (+0.87%) ▲|HD309.02+3.33 (+1.09%) ▲|HON201.95-0.23 (-0.11%) ▼|IBM242.75+8.73 (+3.73%) ▲|INTC103.05+2.73 (+2.72%) ▲|INTU322.30+9.53 (+3.05%) ▲|ISRG371.30+10.84 (+3.01%) ▲|JNJ265.82-0.54 (-0.20%) ▼|JPM356.26+2.70 (+0.76%) ▲|KO88.47+0.64 (+0.73%) ▲|LIN466.99+5.37 (+1.16%) ▲|LLY1,118.14-4.86 (-0.43%) ▼|LMT524.52-5.60 (-1.06%) ▼|LOW196.94+0.35 (+0.18%) ▲|LRCX299.05+1.04 (+0.35%) ▲|MA572.42+7.05 (+1.25%) ▲|MCD252.83-0.22 (-0.09%) ▼|MDLZ62.38-0.09 (-0.14%) ▼|MDT90.78-0.84 (-0.91%) ▼|META649.36+4.98 (+0.77%) ▲|MMM164.85+1.99 (+1.22%) ▲|MO69.00+0.21 (+0.30%) ▲|MRK144.46-0.26 (-0.18%) ▼|MS214.50+1.84 (+0.87%) ▲|MSFT496.93+4.49 (+0.91%) ▲|MU975.69-1.72 (-0.18%) ▼|NEE82.39-0.06 (-0.07%) ▼|NFLX77.51+1.50 (+1.97%) ▲|NKE36.89+0.27 (+0.72%) ▲|NOW132.81+1.64 (+1.25%) ▲|NVDA218.51+0.15 (+0.07%) ▲|ORCL151.13-1.81 (-1.18%) ▼|PEP136.28-0.37 (-0.27%) ▼|PFE27.62-0.03 (-0.12%) ▼|PG145.07+2.10 (+1.47%) ▲|PLTR167.54+1.68 (+1.02%) ▲|PM192.92+3.15 (+1.66%) ▲|QCOM182.35+5.47 (+3.09%) ▲|RTX197.48-0.64 (-0.32%) ▼|SBUX98.82-0.41 (-0.41%) ▼|SCHW107.02-0.31 (-0.29%) ▼|SO87.20-0.55 (-0.63%) ▼|SPG205.02+0.35 (+0.17%) ▲|T26.05+0.50 (+1.96%) ▲|TMO613.07+9.89 (+1.64%) ▲|TMUS183.34+6.18 (+3.49%) ▲|TSLA365.06+1.50 (+0.41%) ▲|TXN268.45+9.63 (+3.72%) ▲|UBER71.80-0.76 (-1.05%) ▼|UNH378.39-9.89 (-2.55%) ▼|UNP284.76-1.02 (-0.36%) ▼|UPS99.95-0.03 (-0.03%) ▼|USB62.84+0.43 (+0.68%) ▲|V371.10+3.89 (+1.06%) ▲|VZ50.52+0.55 (+1.09%) ▲|WFC90.12+0.67 (+0.74%) ▲|WMT107.14+1.41 (+1.33%) ▲|XOM165.30+0.07 (+0.04%) ▲|AAPL332.56+5.99 (+1.83%) ▲|ABBV257.01+2.01 (+0.79%) ▲|ABT102.12-1.24 (-1.20%) ▼|ACN183.71+5.80 (+3.26%) ▲|ADBE253.64+4.81 (+1.93%) ▲|AMAT457.52+3.51 (+0.77%) ▲|AMD516.23+12.63 (+2.51%) ▲|AMGN378.14-4.33 (-1.13%) ▼|AMT178.05+5.07 (+2.93%) ▲|AMZN257.23+5.34 (+2.12%) ▲|AVGO362.85+2.02 (+0.56%) ▲|AXP324.25+3.54 (+1.10%) ▲|BA210.62+5.82 (+2.84%) ▲|BAC62.73+0.17 (+0.26%) ▲|BKNG174.01+0.10 (+0.06%) ▲|BLK1,081.85+19.45 (+1.83%) ▲|BMY63.47-0.28 (-0.44%) ▼|BNY162.85+0.26 (+0.16%) ▲|BRK-B509.53+2.53 (+0.50%) ▲|C138.96+0.46 (+0.33%) ▲|CAT819.79+14.79 (+1.84%) ▲|CL86.45-1.45 (-1.65%) ▼|CMCSA25.16-0.01 (-0.04%) ▼|COF208.31+1.20 (+0.58%) ▲|COP136.75-0.30 (-0.22%) ▼|COST905.17+2.79 (+0.31%) ▲|CRM248.34+5.34 (+2.20%) ▲|CSCO111.64+4.20 (+3.91%) ▲|CVS94.47-0.82 (-0.86%) ▼|CVX213.94+1.18 (+0.55%) ▲|DE676.98-0.96 (-0.14%) ▼|DHR200.43-0.11 (-0.05%) ▼|DIS106.50+0.68 (+0.64%) ▲|DUK119.41+0.04 (+0.03%) ▲|EMR152.04+3.67 (+2.47%) ▲|FDX312.41+0.61 (+0.20%) ▲|GD356.43+2.18 (+0.62%) ▲|GE324.16+0.01 (+0.00%) ▲|GEV956.03+32.12 (+3.48%) ▲|GILD143.94-0.87 (-0.60%) ▼|GM85.70-0.42 (-0.49%) ▼|GOOG336.04+5.65 (+1.71%) ▲|GOOGL339.05+6.45 (+1.94%) ▲|GS1,028.66+8.89 (+0.87%) ▲|HD309.02+3.33 (+1.09%) ▲|HON201.95-0.23 (-0.11%) ▼|IBM242.75+8.73 (+3.73%) ▲|INTC103.05+2.73 (+2.72%) ▲|INTU322.30+9.53 (+3.05%) ▲|ISRG371.30+10.84 (+3.01%) ▲|JNJ265.82-0.54 (-0.20%) ▼|JPM356.26+2.70 (+0.76%) ▲|KO88.47+0.64 (+0.73%) ▲|LIN466.99+5.37 (+1.16%) ▲|LLY1,118.14-4.86 (-0.43%) ▼|LMT524.52-5.60 (-1.06%) ▼|LOW196.94+0.35 (+0.18%) ▲|LRCX299.05+1.04 (+0.35%) ▲|MA572.42+7.05 (+1.25%) ▲|MCD252.83-0.22 (-0.09%) ▼|MDLZ62.38-0.09 (-0.14%) ▼|MDT90.78-0.84 (-0.91%) ▼|META649.36+4.98 (+0.77%) ▲|MMM164.85+1.99 (+1.22%) ▲|MO69.00+0.21 (+0.30%) ▲|MRK144.46-0.26 (-0.18%) ▼|MS214.50+1.84 (+0.87%) ▲|MSFT496.93+4.49 (+0.91%) ▲|MU975.69-1.72 (-0.18%) ▼|NEE82.39-0.06 (-0.07%) ▼|NFLX77.51+1.50 (+1.97%) ▲|NKE36.89+0.27 (+0.72%) ▲|NOW132.81+1.64 (+1.25%) ▲|NVDA218.51+0.15 (+0.07%) ▲|ORCL151.13-1.81 (-1.18%) ▼|PEP136.28-0.37 (-0.27%) ▼|PFE27.62-0.03 (-0.12%) ▼|PG145.07+2.10 (+1.47%) ▲|PLTR167.54+1.68 (+1.02%) ▲|PM192.92+3.15 (+1.66%) ▲|QCOM182.35+5.47 (+3.09%) ▲|RTX197.48-0.64 (-0.32%) ▼|SBUX98.82-0.41 (-0.41%) ▼|SCHW107.02-0.31 (-0.29%) ▼|SO87.20-0.55 (-0.63%) ▼|SPG205.02+0.35 (+0.17%) ▲|T26.05+0.50 (+1.96%) ▲|TMO613.07+9.89 (+1.64%) ▲|TMUS183.34+6.18 (+3.49%) ▲|TSLA365.06+1.50 (+0.41%) ▲|TXN268.45+9.63 (+3.72%) ▲|UBER71.80-0.76 (-1.05%) ▼|UNH378.39-9.89 (-2.55%) ▼|UNP284.76-1.02 (-0.36%) ▼|UPS99.95-0.03 (-0.03%) ▼|USB62.84+0.43 (+0.68%) ▲|V371.10+3.89 (+1.06%) ▲|VZ50.52+0.55 (+1.09%) ▲|WFC90.12+0.67 (+0.74%) ▲|WMT107.14+1.41 (+1.33%) ▲|XOM165.30+0.07 (+0.04%) ▲|
26.7 C
New York
Friday, September 11, 2026

Tag: development

Antag Therapeutics presents positive Phase 1 results at the 2026 Scientific Sessions of the American Diabetes Association for AT7687, a first-in-class GIPR antagonist

Copenhagen, Denmark, 7 June 2026 – Antag Therapeutics (“Antag” or “the Company”), advancing personalized and flexible obesity treatment through GIP receptor antagonism, today presented key Phase 1 and preclinical data for AT7687 at the 2026 Scientific Sessions of the American Diabetes Association®, held in New Orleans, Louisiana from June 5-8, 2026.

Lilly’s Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage...

In ATTAIN-1, women in perimenopause taking Foundayo lost up to 30.4 lbs (14.4%) and those in post-menopause lost up to 28.2 lbs (14.1%)In ATTAIN-2, women taking Foundayo lost significant...

IBA‑UIBC Cup of Bakers 2027 “Golden Statue Cup” China Selection – Hong Kong & Macao SAR Selection Competition Successfully Held in Hong Kong

Competition Highlights Industry Excellence and Strengthens International Exchange in the Baking Sector HONG KONG, June 7, 2026 /PRNewswire/ -- The Final of the IBA‑UIBC Cup...

Dongfeng Liuzhou Motor’s 10th “67 Brand Customer Day” Advancing New Pathways for Global Growth

LIUZHOU, China, June 7, 2026 /PRNewswire/ -- On June 7, Dongfeng Liuzhou Motor (DFLZM) hosted its 10th "67 Brand Customer Day" in Liuzhou. More than...

Dongfeng Liuzhou Motor’s 10th “67 Brand Customer Day” Advancing New Pathways for Global Growth

LIUZHOU, China, June 7, 2026 /PRNewswire/ -- On June 7, Dongfeng Liuzhou Motor (DFLZM) hosted its 10th "67 Brand Customer Day" in Liuzhou. More than...

Looney Tunes™ Land Now Open at Six Flags Magic Mountain

Complete reimagining of the park's family area offers a brand-new experience that encourages exploration across four distinct areas with loveable Looney Tunes™ characters at its heartLooney...

A New Era Begins: Cal Poly Unveils the John Madden Football Center

$45 Million Facility Honors Legendary Alumnus and Elevates the Future of Mustang FootballSAN LUIS OBISPO, Calif., June 6, 2026 /PRNewswire/ -- Cal Poly Athletics...

The American Diabetes Association Announces Winners of the Innovation Challenge

NEW ORLEANS, June 6, 2026 /PRNewswire/ -- Today, from the main stage at the organization's 2026 Scientific Sessions, the American Diabetes Association® (ADA) announced...

The Adam Foundation Commits $750,000 to the FIFA Global Citizen Education Fund, Helping Drive the Initiative Past the $50 Million Mark

Announcement made at Global Citizen Live: Rio de Janeiro ahead of the FIFA World Cup FinalLONDON, June 7, 2026 /PRNewswire/ -- The Adam Foundation,...

Real-World Evidence of Eversense 365 Presented at ADA Demonstrating Strong Performance and Patient Impact in Both Open and Closed Loop Systems

Eversense 365 delivered favorable glucometrics compared to other open and closed loop systems, validating the one-year CGM’s differentiated approach and high performance 

82% of Adults with Type 2 Diabetes Not on Insulin Improve Blood Glucose Levels with Continuous Glucose Monitoring

New Study Highlights Potential of CGM to Help Patients Improve Diabetes Management in Primary Care SettingsNEW ORLEANS, June 6, 2026 /PRNewswire/ -- A new...

Lilly’s triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity...

In TRIUMPH-1, participants on retatrutide 12 mg lost an average of 70.3 lbs (28.3%) over 80 weeks, with 65.3% achieving a BMI below 30,...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsDevelopment